ReviewTranslational oncology2022
Therapeutic approaches for the treatment of head and neck squamous cell carcinoma-An update on clinical trials.
Review in Translational oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 83 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
83 citing papers in PubMed, 116 citations in OpenAlex.
- Head and neck squamous cell carcinoma: current and emerging therapeutic strategies.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- The efficacy of concurrent chemoradiotherapy with or without nimotuzumab in high-risk patients with locally advanced head and neck squamous cell carcinoma post-surgery: A real-world study.Precision radiation oncology · 2026Article
- Article
- Metabolic and Clinical-Nutritional Correlation Patterns in Relation to 3-Year Disease-Free Survival in Locally Advanced Head and Neck Squamous Cell Carcinoma: A Preliminary Analysis.International journal of molecular sciences · 2026Article
- Toward a Better Paradigm for Head and Neck Cancer Treatment Applying AI (HNC-TACTIC): Protocol for an International Cohort Study of Electronic Health Records.JMIR research protocols · 2026Observational
- Hydrogels in head and neck cancer: Innovations and translational advances in research and therapy.Biomaterials · 2026Review
- Plasma COL3A1 propeptide as a promising prognostic marker in oral squamous cell carcinoma.Scientific reports · 2026Article
- Comprehensive analysis and validation of the prognostic value of glycosylation- and mitophagy-related genes for head and neck squamous cell carcinoma.Translational cancer research · 2026Article
- Gallic acid chemoprevention of oral carcinogenesis is associated with HSD11β2 upregulation and immune remodeling.Scientific reports · 2026Article
- Prognostic and Immunologic Characteristics of Head and Neck Squamous Cell Carcinoma Based on Disulfidptosis-Related lncRNAs.Molecular biotechnology · 2026Article
- Quetiapine inhibits the oxidative phosphorylation in head and neck squamous cell carcinoma through suppressing NAT10-mediated ac4C modification.Translational cancer research · 2026Article
- Targeted nanocomposite delivery system of amygdalin using chitosan/reduced graphene oxide-zinc oxide/hyaluronic acid for treatment of head and neck squamous cell carcinoma.BMC oral health · 2026Article
- Machine learning-based treatment outcome prediction in head and neck cancer using integrated noninvasive diagnostics.International journal of computer assisted radiology and surgery · 2026Article
- State of the Art of Systemic Therapy in HPV-Positive Oropharyngeal Squamous Cell Carcinoma: A Scoping Review.Diseases (Basel, Switzerland) · 2026Review
- Patterns of response in head and neck cancer subregions using daily Quantitative MRI from MR-guided radiation therapy.Clinical and translational radiation oncology · 2026Article
- Advances in Understanding How RhoB Regulates Akt Inhibition Efficacy in NSCLC.Current cancer drug targets · 2026Article
- Divergent immuno-landscapes: comparing the tumor microenvironment of Indian and Western HNSCC patients.Frontiers in cell and developmental biology · 2026Review
- CD47 blockade (ALX301) enhances immunoradiotherapy response in HPV negative head and neck squamous cell carcinoma.PloS one · 2026Article
- The Impact of Senescence-Associated Secretory Phenotype (SASP) on Head and Neck Cancers: From Biology to Therapy.Cancers · 2025Review
- Inverse Correlation between Endoplasmic Reticulum Stress Intensity and Antitumor Immune Response with Ruthenium(II)-Based Photosensitizers for the Photodynamic Therapy of Head and Neck Squamous Cell Carcinoma.Journal of medicinal chemistry · 2025Article
23 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Head and neck squamous cell carcinoma (HNSCC) is the sixth most common non-skin cancer with a tobacco consumption and infection with high-risk human papillomavirus (HPV) being major risk factors. Despite advances in numerous therapy modalities, survival rates for HNSCC have not improved considerably; a vast number of clinical outcomes have demonstrated that a combination strategy (the most well-known docetaxel, cisplatin, and 5-fluorouracil) is the most effective treatment choice. Immunotherapy that targets immunological checkpoints is being tested in a number of clinical trials, either alone or in conjunction with chemotherapeutic or targeted therapeutic drugs. Various monoclonal antibodies, such as cetuximab and bevacizumab, which target the EGFR and VEGFR, respectively, as well as other signaling pathway inhibitors, such as temsirolimus and rapamycin, are also being studied for the treatment of HNSCC. We have reviewed the primary targets in active clinical studies in this study, with a particular focus on the medications and drug targets used.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.